Beam Therapeutics Inc. (NASDAQ:BEAM) shares jumped 12% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation ...

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101.

Collaboration Revenue: Collaboration revenue was $1.5 million for the three months ended June 30, 2025, as compared to no collaboration revenue for the three months ended June 30, 2024. The increase ...

Neurizon starts manufacturing initial registration batch of NUZ-001 tablets to potentially treat ALS and related ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

BRISBANE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...